focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Contractors at Zulu have agreed to accept payment of US$2 million dollars of invoices, in new ordinary shares of the Company. Accordingly, the Company has today settled payment of US$2 million (equivalent to £1.57 million) in invoices through the issue of 983,500,000 new ordinary shares of the Company at the price of 0.16 pence per ordinary share ("Settlement Shares"). The Settlement Shares will, when issued, rank pari passu in all respects with the existing ordinary shares.
Eek - come back in July
It's on youtube now - still none the wiser to be honest. Quite a lot of smoke and mirrors - sounds like there is quite a lot of news in the pipeline, but he was saying the same in the Sunday Roast podcast a few months back.
They are definitely in the right space though.
Https://www.cannabiz.com.au/uk-patient-numbers-demand-and-consumption-surge-to-all-time-high/
The approval of the trial protocol, and in particular the data capture and dosage control methodologies, has also led to further exploration of the potential use of the protocol to treat other conditions. Discussions are ongoing with a healthcare provider about a novel application for the protocol.
Be interested to know what those other conditions are and if this will create a material delay to the planned commencement of the main CANPAIN trial?
And this:
On 8 March 2024, the Group disposed of its investment in Harley Street (CPC) Limited for a consideration of £500,000 payable over three years. At the time of the disposal, the only activity conducted by Harley Street (CPC) Limited was the operation of a CQC registered clinic. The assets relating to the CANPAIN Trial had been transferred to Celadon Property Co Limited during 2023.
The prospect of the CANPAIN protocol being used in other jurisdictions, as well as for the treatment of other conditions, further demonstrates the vast potential that cannabis-based medicines offer Celadon, national health providers, and most importantly, patients.
How do CEL benefit from farming out their protocol?
Some questions:
The Group has started to deliver on its commercial Supply Agreements and has several additional customer contracts in negotiation demonstrating the continuing and increasing demand for high-quality UK grown cannabis products.
Well what year will they be getting their products, if Phase I is meeting existing contracts and Phase II will complete in 2025 and will be used for the 24m contract?
Looks pretty bullish to me, anyone any ideas why this would be the case?
It is expected that First Admission will occur on or around 15 May 2024, with the remaining 714,286 shares being admitted in three instalments on 10 June, 15 July and 12 August 2024
Https://www.lse.co.uk/rns/CEL/fundraise-rcf-extension-termination-of-cln-tvr-n9jsvyf94i2gloe.html
This is how you do it
They have literally said they are coming off the markets for a few years, yet you come up with this stuff:
In the meantime, the BOD are planning a great big F**K Y** to the City of London with a NASDAQ listing. My money is on a NASDAQ listing in Q4 2024 at an IPO price matching Edison’s TP.
I might be some on the basis I will be locked out for a few years I.e. Genuine long term hold, but stop trying to ramp.